Healthcare
Live Price
Offline$1.87
-0.00% today
1Y Change
+1.82%
Window
Jun 26, 2025 → Jun 17, 2026
Coverage: 245 bars · Jun 26, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Inhibikase Therapeutics, Inc. (IKT) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $1.87 and up 1.8% across the available one-year price window (Jun 26, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +57.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +57.8%, free cash flow -45.1% with operating margin 0.0% and ROIC -26.6%. Stock Foundry combines IKT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IKT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IKT Max Drawdown
-30.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for IKT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.1M
+2411.8% YoY
FY Net Income
-$14.8M
+18.1% YoY
Free Cash Flow
-$14.3M
+18.7% YoY
Revenue Growth
+0.0%
EPS Growth
+57.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 261K | 123K | 3M |
| Gross Profit | -60K | -26K | -13M | 117K | -8M |
| Operating Income | -46M | -29M | -20M | -18M | -15M |
| EBITDA | -46M | -27M | -20M | -18M | 0 |
| Net Income | -48M | -28M | -19M | -18M | -15M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 139M | 56M | 9M | 7M | 41M |
| Total Assets | 181M | 99M | 15M | 25M | 42M |
| Total Liabilities | 8M | 4M | 4M | 4M | 4M |
| Shareholder Equity | 173M | 95M | 11M | 21M | 38M |
| Total Debt | 0 | 111K | 622K | 351K | 249K |
| Net Debt | -139M | -56M | -9M | -7M | -41M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
14M
+17.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
14M
+18.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.